Fate Therapeutics Inc Dossier - Source-backed chat

Fate Therapeutics Inc

FATENASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.01

Intrinsic Value $2.13median of 2 methodsbased on filings through 30 Jun 2026

Market Price $2.30Price as of 1 Oct 2026

Near fair valueIntrinsic value is 8% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $275.6M

Enterprise Value $243.2M

Shares Outstanding 120.6M diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Fate Therapeutics is a pioneer in induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies. The company is undergoing a highly promising strategic pivot from oncology toward autoimmune diseases, led by its lead asset FT819 (an anti-CD19 CAR T-cell therapy). FT819 has demonstrated rapid and sustained clinical improvement in systemic lupus erythematosus (SLE) with a favorable safety profile and the unique ability to be administered in an outpatient setting without intensive conditioning chemotherapy. Backed by a strong cash runway extending into 2028, disciplined cost management, and key regulatory tailwinds (including FDA RMAT designation and selection into the highly competitive CDRP program), Fate is well-positioned to transition from a clinical-stage platform to a commercial-stage leader in off-the-shelf cell therapy.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.20

Mean target$5.41

High · most bullish analyst$8.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.2020%

The Phase 2 RECLAIM-LN trial faces enrollment delays or clinical setbacks, such as unexpected safety signals or lower-than-expected complete renal response rates. Regulatory alignment under the CDRP program slows down due to manufacturing or CMC hurdles. The cash burn rate accelerates, forcing a highly dilutive equity raise before late 2027, which depresses the stock price toward its historical lows.

Base CaseCentral scenario

$5.4150%

Matches the consensus mean

Fate successfully initiates the Phase 2 RECLAIM-LN trial in 2H 2026 and maintains steady patient enrollment. FT819 continues to show a strong safety profile with no dose-limiting toxicities or severe CRS/ICANS. The cash runway remains secure into 2028 due to disciplined operating expense management. Early clinical readouts from next-generation programs (FT839 and FT836) provide additional platform validation, supporting a steady upward trajectory toward consensus analyst targets.

Bull CaseUpside scenario

$8.0030%

FT819 achieves outstanding efficacy in the Phase 2 RECLAIM-LN trial, demonstrating a high complete renal response (CRR) rate at six months. Outpatient administration without intensive conditioning chemotherapy drives rapid clinical adoption, positioning FT819 as the gold standard for refractory lupus nephritis. The FDA grants accelerated approval by 2028, and the company successfully leverages its clonal master cell bank platform to manufacture uniform, cost-effective doses at scale, leading to a major upward re-rating of the stock.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated iPSC platform utilizing clonal master cell banks, enabling scalable, uniform, and cost-effective off-the-shelf manufacturing.
Lead asset FT819 has received FDA RMAT designation and selection into the competitive CDRP program, accelerating its regulatory pathway.
Strong clinical data in SLE demonstrating deep B-cell depletion and clinical reset without intensive conditioning chemotherapy, enabling outpatient administration.
Robust financial position with $174.8M in cash and investments, providing an extended operating runway into 2028.

Key Investment Risks

Clinical trial execution risks, particularly around patient enrollment timelines for the Phase 2 RECLAIM-LN trial.
Regulatory and CMC hurdles associated with scaling up iPSC-derived cell therapy manufacturing to meet commercial standards.
Intense competition in the autoimmune cell therapy space from both autologous CAR T-cell therapies and other allogeneic platforms.
Pre-commercial stage with de minimis revenue, making the company entirely dependent on capital markets or strategic partnerships for long-term funding.

Thesis Invalidation Triggers

Failure to initiate patient dosing in the Phase 2 RECLAIM-LN trial by the end of 2026.
Occurrence of severe adverse events (such as Grade >2 CRS, ICANS, or GvHD) in patients treated with FT819.
A material acceleration in cash burn that reduces the operating runway to less than 12 months without a clear path to non-dilutive funding.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.